Study identifier:D6402C00002
ClinicalTrials.gov identifier:NCT04686591
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-label Study of Absolute Bioavailability and Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]AZD9977 in Healthy Male Subjects
cardiovascular disease
Phase 1
Yes
[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq), AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
Male
8
Interventional
30 Years - 60 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Basic Science
Verified 01 Jun 2022 by AstraZeneca
AstraZeneca
Quotient Sciences Limited
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD9977 In Period 1, one 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capsules) and one 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL). In Period 2, one 100 mg dose of [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq). | Drug: AZD9977 capsule 50 mg 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles) Other Name: AZD9977 Drug: [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) One 100 µg dose of [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) Other Name: [14C]AZD9977 |